Raymond James Downgrades Meridian Bioscience To Underperform

Analysts at Raymond James downgraded Meridian Bioscience, Inc. VIVO from Market Perform to Underperform. Meridian Bioscience shares have dropped 36.96% over the past 52 weeks, while the S&P 500 index has gained 12.39% in the same period. Meridian Bioscience's shares rose 0.86% to close at $16.46 on Wednesday.